Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

    September 17, 2025 | AstraZeneca, Merck, clinical trials, patient recruitment 

    Kate Shaw comments on the latest news about AstraZeneca and Merck’s decision to hold planned investments in the UK

    - PMLiVE

    The recent decision by pharmaceutical company AstraZeneca to pause a planned £200 million expansion of its Cambridge research site and the announcement by Merck (known as MSD in Europe) to withdraw its life science research operation from the UK have been described as a ‘tragedy’ by Innovative Trials’ founder and CEO, Kate Shaw.

     

    Read more here: https://innovativetrials.com/astrazeneca-and-merck-decision-to-disinvest-in-uk-is-a-tragedy-for-british-research-and-innovation-says-innovative-trials/

    This content was provided by Innovative Trials

    Company Details

    - PMLiVE

    Innovative Trials

    Email
    Website

     Latest Content from  Innovative Trials 

    Innovative Trials’ CEO wins Women in Pharma Award

    Kate Shaw, founder and CEO of Innovative Trials, a global clinical trial patient recruitment and retention company, won the ‘Woman in Pharma’ at the Pharma Industry Awards UK. She was...

    Innovative Trials nominated finalist at the Pharma Industry Award

    Patient recruitment company, Innovative Trials, has been nominated as a finalist in 2 categories at the Pharma Industry Award Read the full press release 👉🏽 https://bit.ly/3MdzBwf

    Patient Recruitment & Retention Webinar for Influenza Studies

    Join the upcoming webinar which will discuss key patient recruitment & retention challenges and solutions for upcoming influenza studies.

    [Free Whitepaper] 6 reasons why direct patient support is a ‘must have’ for your clinical trials

    This white paper explores the importance of patient-first services and why direct patient support is crucial for the success of sponsors’ clinical trials. Download it for FREE 👉🏽  https://innovativetrials.com/six-reasons-why-direct-patient-support-is-a-must-have-for-your-clinical-trials/ 

    Uniting Communities for Rare Disease Clinical Trial Success

    Step into the realm of innovation and collaboration in patient recruitment and retention with our upcoming webinar, "Bridging Boundaries: Uniting Communities for Rare Disease Clinical Trial Success." Delve deep into...

    Patient Recruitment & Retention Strategies in the 2024 Clinical Trial Landscape

    In the landscape of the clinical trial industry in 2024, persistent challenges persist in the realms of patient recruitment and retention. These hurdles, having endured over several years, continue to...

    Solving your biggest patient recruitment and retention challenges

    Clinical trial patient recruitment and retention remains one of the key challenges to successfully bringing a new therapeutic to market. An estimated 85% of clinical trials face delays due to...

    Innovative Trials Announces New Charity Partnerships

    Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

    Free Live Webinar – Uniting Communities for Rare Disease Clinical Trial Success

    Join this live webinar focusing on patient recruitment and retention in rare disease trials.

    Retention Patch Program

    A partnership between Innovative Trials and the non-profit Oliver Patch Project to boost retention in pediatric studies